Profile
AGRX ZTS TAK HLN TEVA ITCI
Company Name Agile Therapeutics, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $10.43M $73.61B $47.68B $46.95B $17.60B $13.95B
Employees 0.02K 13.80K 49.28K 25.41K 33.89K 0.86K
CEO Mr. Alfred F. Altomari Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
AGRX ZTS TAK HLN TEVA ITCI
Quant Rating Score 2 3 3 2 1 1
Quant Rating Sell Neutral Neutral Sell Strong Sell Strong Sell
Trading
AGRX ZTS TAK HLN TEVA ITCI
Last Close $1.51 $164.39 $14.9 $10.39 $16.1 $131.24
High 52 $1.51 $196.48 $15.17 $10.69 $22.77 $131.28
Low 52 $0.27 $145.54 $12.6 $8.01 $12.78 $64.37
Price vs. 52 Week High 0 % -16.33 % -1.78 % -2.81 % -29.29 % -0.03 %
Price vs. 52 Week Low 459.26 % 12.95 % 18.25 % 29.71 % 25.98 % 103.88 %
Total Return
AGRX ZTS TAK HLN TEVA ITCI
1 Month Return 0 % -5.46 % 12.37 % 5.38 % -1.47 % 2.56 %
3 Month Return 0 % -7.74 % 11.03 % 6.45 % -2.42 % 58.06 %
6 Month Return 0 % -13.8 % 0.54 % 0.1 % -10.61 % 74.47 %
9 Month Return 321.67 % -6.52 % 11.69 % 24.88 % -6.5 % 92.43 %
YTD Return 0 % 0.9 % 12.54 % 8.91 % -26.95 % 57.14 %
1 Year Return 107.15 % -9.35 % 3.69 % 19.98 % 19.35 % 103.88 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AGRX ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.09 % 4.28 % 0.02 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 2.05 % 1.76 % - 2.5 % -227.26 %
Dividend Per Share (TTM) - 1.8 % 192 % 0.06 % - -
Payout Ratio (TTM) - 31.62 % 145.09 % - - -
Profitability
AGRX ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM 63.63 % 69.85 % 54.74 % 61.06 % 48.74 % 91.63 %
Return on Assets TTM -105.97 % 17.46 % 1.38 % 3.62 % -4.17 % -5.46 %
Return on Equity TTM 104.04 % 49.65 % 2.83 % 7.27 % -26.15 % -7.4 %
Return on Capital Employed TTM 120.33 % 24.27 % 3.62 % 7.66 % -1.14 % -10.05 %
Net Income Per EBT TTM 100 % 79.35 % 89.75 % 67.34 % 127.75 % 100.64 %
EBT Per Ebit TTM 116.98 % 119.26 % 49.18 % 84.34 % 423.43 % 63.57 %
EBIT Per Revenue TTM -62.85 % 28.38 % 10.3 % 18.92 % -1.83 % -17.15 %
Cash Flow To Debt Ratio TTM - 43.79 % 22.2 % - 6.9 % -430.93 %
Receivables Turnover TTM 4.74 7.03 6.23 5.26 5.41 4.09
Payables Turnover TTM 0.47 6.45 4.5 1.22 3.85 2.18
Inventory Turnover TTM 1.35 1.21 1.66 2.99 2.82 2.17
Fixed Asset Turnover TTM 7648.23 % 256.4 % 226.93 % 603.65 % 334.34 % 4569.25 %
Asset Turnover TTM 144.14 % 65.01 % 30.31 % 33.66 % 42.07 % 49.79 %
Operating Cash Flow Per Share TTM -0.25 6.5 678.77 - 1.1 -0.71
Free Cash Flow Per Share TTM -0.25 5.06 484.07 - 0.66 -0.71
Cash Per Share TTM 41.54 % 437.03 % 33271.95 % 5.75 % 291.26 % 970.67 %
Operating Cash Flow Sales Ratio TTM -7.91 % 31.9 % 23.47 % - 7.54 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 77.82 % 71.32 % - 60.06 % 100.44 %
Cash Flow Coverage Ratios TTM - 43.79 % 22.2 % - 6.9 % -430.93 %
Price To Free Cash Flows Ratio TTM -6.11 32.03 9.28 - 23.05 -189.86
Price To Operating Cash Flows Ratio TTM -6.07 25.28 6.61 - 13.69 -184.96
Price Cash Flow Ratio TTM -6.07 25.28 6.61 - 13.69 -184.96
Income Statement (TTM)
AGRX ZTS TAK HLN TEVA ITCI
Revenue $0.02B $9.26B $4263.76B $11.3B $16.54B $0.68B
Gross Profit $0.01B $6.54B $2832.26B $6.96B $8.06B $0.62B
Gross Profit Ratio 54.2% 70.62% 66.4% 61.59% 48.74% 91.63%
EBITDA $-0.02B $3.86B $874.6B $2.35B $-0.3B $-0.12B
Net Income $-0.01B $2.49B $144.07B $1.05B $-1.64B $-0.07B
EPS Diluted -6.71 5.47 91.16 0.11 -1.45 -0.72
Balance Sheet (MRQ)
AGRX ZTS TAK HLN TEVA ITCI
Long Term Debt $0B $5.39B $5029.93B $8.8B $16.3B $0.01B
Total Liabilities $0.03B $9.47B $7834.79B $17.33B $33.61B $0.22B
Total Equity $-0.02B $4.77B $7274.01B $16.73B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.07B $0B $0.69B
Total Debt $0B $6.74B $4843.75B $9.46B $18.08B $0.02B
Total Assets $0.01B $14.24B $15108.79B $34.06B $39.33B $1.37B
Cash Flow Statement (TTM)
AGRX ZTS TAK HLN TEVA ITCI
Net Income $-0.01B $2.5B $144.07B $1.11B $-1.96B $-0.07B
Inventory $-0B $-0.04B $-115.74B $-0.13B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0.01B $2.95B $716.34B $2.1B $1.25B $-0.07B
Capital Expenditure $0B $-0.66B $-480.73B $-0.34B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.485
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AKAN Akanda Corp. 1.4702
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 11.44
ALVOW Alvotech 1.5
AMPH Amphastar Pharmaceuticals, Inc. 26.975
AMRX Amneal Pharmaceuticals, Inc. 8.85
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 62.645
AQST Aquestive Therapeutics, Inc. 2.65
ASRT Assertio Holdings, Inc. 0.765
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 7.855
AYTU Aytu BioPharma, Inc. 1.27
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AGRX
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 122.025
VXF Vanguard Extended Market Index Fund 0 173.535
VQNPX Vanguard Growth and Income Fund 0 58.51
VGIAX Vanguard Quantitative Funds - Vanguard Growth and Income Fund 0 95.5
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 131.19
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 131.2
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
VEMPX Vanguard Extended Market Index InstlPlus 0 323.75
Unlock